Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2010

Fast Forward and JDRF Team Up with Axxam for MS and Diabetes Treatments

  • Fast Forward, the commercial drug-development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation have entered a partnership with Axxam to develop new treatments for multiple sclerosis (MS) and type 1 diabetes (T1D). Axxam will screen its chemical library to identify compounds that modulate Kv1.3 ion channel activities.

    Recent studies have found that immune cells in MS and T1D contain high levels of the ion channel Kv1.3. Subsequently, the hyperactivity of this channel contributes to the dysfunction of the immune system in MS and T1D.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »